Bayesian BE Assessment [Study As­sess­ment]

posted by DavidManteigas – Portugal, 2017-03-14 12:45 (2889 d 12:47 ago) – Posting: # 17153
Views: 2,580

Hi Ben,

If current frequentist methods for studies where bayesian analysis may fit (two-stage) are full of controversies in the regulators point of view, I can't even imagine if you introduce bayesian methods to them in those cases :-D

I'm not a frequentist phanatic. I believe both approaches are valid depending on the problems and study designs under consideration. Regarding bioequivalence however, I don't see how bayesian inference may add any value. The same is not true for therapeutic equivalence studies (biosimilars), where I believe bayesian methods would be very advantageous since you already "have" prior "information" regarding treatments.

Regards,
David

Complete thread:

UA Flag
Activity
 Admin contact
23,376 posts in 4,912 threads, 1,662 registered users;
228 visitors (0 registered, 228 guests [including 21 identified bots]).
Forum time: 01:32 CET (Europe/Vienna)

Science is what you know.
Philosophy is what you don’t know.    Bertrand Russell

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5